Abzena and BioXpress Therapeutics partner to provide global biosimilar support
The combined capabilities will offer flexibility and innovation from small-scale biosimilar development through to large-scale manufacturing
Abzena and BioXpress Therapeutics have formed a partnership to support biosimilar development for third-party customers.
The partnership creates an integrated solution between two service providers with expertise in biosimilar development and good manufacturing practice (GMP), allowing for a simplified drug development timelines for the biosimilars market.
Furthermore, the combined expertise will provide a flexible and innovative approach from small-scale biosimilar development through to large-scale manufacturing.
Biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.
According to Abzena's CEO, Jonathan Goldman, the combined services will provide customers with a "de-risked approach" to biosimilar development, through to clinical development and ultimately to the market.”
Related News
-
News Rebuilding the United States' pharma infrastructure – CPHI North America 2023 preview
As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape. ... -
News Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a... -
News To recruit or to retain - where is the pharma talent going?
Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. -
News NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, w...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance